Magnesium l-threonate supports cognitive function in older adults, study shows

Summary

This randomized, double-blind, placebo-controlled trial was designed to investigate the effect of magnesium l-threonate on age-related cognitive decline in otherwise healthy older adults.

For this study, researchers enrolled 51 older adults, aged 50-70 years, with self-reported complaints of cognitive decline (memory and concentration), anxiety and poor sleep quality. Exclusion criteria included Alzheimer’s disease, dementia, heart disease, and other chronic diseases.

The participants were randomly assigned to one of two treatment groups for 12 weeks: magnesium l-threonate (MMFS-01) or placebo. The dosage was set to correspond to approximately 25 mg/kg/day. Participants weighing between 50-70 kg took 1.5 g/day of MMFS-01; those weighing between 70-100 kg took 2 g/day. Cognitive ability, sleep quality, and emotional state were evaluated. Overall cognitive ability was determined by a composite score of clinically validated tests in four major cognitive domains (i.e., executive function, working memory, attention, and episodic memory).

A total of 44 participants (86%; 44/51) completed the study and were included in the efficacy analysis. The safety analysis included all 51 enrolled participants. Treatment was well tolerated with mild adverse events more prevalent in the placebo group and primarily related to gastrointestinal upset or infections. No serious adverse events were reported.

Results indicate that, compared to placebo, magnesium l-threonate significantly (P<.05) improved overall cognitive ability as measured by the composite score of cognitive tests. Due to the strong placebo effects on sleep and anxiety, the effects of Magtein® supplementation on sleep and anxiety could not be determined.

These findings indicate a potential role for magnesium l-threonate supplementation (1.5-2 g/day for 12 weeks) for treating age-related cognitive impairment in older adults.